ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature medicine, 2018 - nature.com
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer,. The majority of ARID1A mutations are inactivating …
被引用次数：452 相关文章
[HTML] nih.gov

[HTML][HTML] ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature …, 2018 - ncbi.nlm.nih.gov
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are …
[PDF] researchgate.net

[PDF][PDF] ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge, ZD Nagel… - Nat Med, 2018 - researchgate.net
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer1, 2. The majority of ARID1A mutations are …

[引用][C] ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature Medicine, 2018 - cir.nii.ac.jp
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity
unleashed by immune checkpoint blockade | CiNii Research CiNii 国立情報学研究所 学術情報 …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature Medicine, 2018 - go.gale.com
ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most
commonly mutated genes in cancer. sup. 1, 2. The majority of ARID1A mutations are …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng… - Nature …, 2018 - pubmed.ncbi.nlm.nih.gov
ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most
commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are inactivating …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature …, 2018 - europepmc.org
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng, Z Ge… - Nature …, 2018 - ohsu.elsevierpure.com
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang, Y Peng… - Nature …, 2018 - mdanderson.elsevierpure.com
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are …

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

J Shen, Z Ju, W Zhao, L Wang… - Nature …, 2018 - utsouthwestern.elsevierpure.com
Abstract ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the
most commonly mutated genes in cancer 1, 2. The majority of ARID1A mutations are …